Structure Therapeutics American Depositary SharesNASDAQ: GPCR

Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.

Structure Therapeutics is a clinical-stage biotech developing a small-molecule drug that mimics an important gut hormone. Early results for Structure Therapeutics' lead candidate compare well with Wegovy and experimental weight management treatments.

Structure Therapeutics published some strong data from its weight-loss program. Its candidate preliminarily appears to be more effective than the market leader.

SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the closing of its previously announced upsized underwritten public offering of 10,427,017 American depositary shares (ADSs), each representing three ordinary shares, including the full exercise of the underwriters' option to purchase up to 1,360,045 additional ADSs,  at a public offering price of $52.50 per ADS. The aggregate gross proceeds to Structure Therapeutics from the offering were approximately $547.4 million, before deducting underwriting discounts and commissions and offering expenses. All of the ADSs were offered by Structure Therapeutics.

SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the pricing of its upsized underwritten public offering of 9,066,972 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of $52.50 per ADS. The aggregate gross proceeds to Structure Therapeutics from the offering are expected to be approximately $476.0 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Structure Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,360,045 ADSs at the public offering price, less underwriting discounts and commissions. The offering is expected to close on June 7, 2024, subject to the satisfaction of customary closing conditions.

Jared Holz, Mizuho, joins 'Fast Money' to talk Structure Therapeutics soaring on its GLP-1 data and M&A targets in the obesity drug space.

Contenders are beginning to emerge from the lab, some with the potential to unseat Lilly's Zepbound and Novo's Wegovy.

Structure Therapeutics stock declined sharply due to some data it published. The data show that its flagship drug candidate appears to be safe and effective.

Structure Therapeutics shares plummeted more than 30% after clinical data for its investigational obesity drug failed to meet expectations.   The company's pill GSBR-1290 is part of a class of weight loss drugs known as glucagon-like peptide 1 (GLP-1) agonists, like Novo Nordisk (NYSE:NVO)'s Wgovy and Ozempic and Eli Lilly and Co (NYSE:LLY)'s Mounjaro and Zepbound.